Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas

SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2

(2009) Afshin Dowlati et al.   ANTI-CANCER DRUGS

Neurosphere Formation Is an Independent Predictor of Clinical Outcome in Malignant Glioma

(2009) Dan R. Laks et al.   STEM CELLS

Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis

(2008) Alice N. Scott et al.   ANGIOGENESIS

Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach

(2008) Cristóbal Belda-Iniesta et al.   Clinical & Translational Oncology

Targeting the Epidermal Growth Factor Receptor in High-Grade Astrocytomas

(2008) Will R. Voelzke et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Chemoresistance in gliomas

(2008) Chen Lu et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease

(2008) Robert Lustig et al.   NEURO-ONCOLOGY

Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma

(2008) Daphne A. Haas-Kogan et al.   NEURO-ONCOLOGY